GlassScriptPhysician profile
Steven R Hays
NPI 1174570576
$15,493.73
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,550 · 2022: $5,464 · 2023: $3,828 · 2024: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,320 · Honoraria: $1,380 · Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,320.00 |
| Honoraria | $1,380.00 |
| Food and Beverage | $779.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zambon USA LTD. | $6,823.99 | 2022-2023 | |
| Grifols Shared Services North America, INC. | $5,550.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $2,320.00 | 2023 | Cellex |
| Paragonix Technologies, INC. | $278.73 | 2024 | Pancreaspak, Lungguard, Liverguard |
| United Therapeutics Corporation | $224.75 | 2024 | Steen Solution, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $107.77 | 2023-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.23 | 2023 | Stiolto Respimat, Ofev |
| La Jolla Pharmaceutical Company | $41.67 | 2024 | Giapreza |
| Takeda Pharmaceuticals U.S.A., INC. | $31.19 | 2023 | Glassia |
| Astellas Pharma US INC | $26.51 | 2024 | Cresemba |
| Glaxosmithkline, LLC. | $20.33 | 2022 | |
| Mylan Specialty L.P. | $17.29 | 2024 | Yupelri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.